Aureka Biotechnologies
PrivateLast Round
Series B
Aug 10, 2026
Total Funding Raised
$200M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Aureka Biotechnologies operates in Healthcare & Life Sciences and is based in Laguna Hills, California. Its latest recorded funding round was a Series B round in August 2026.
Aureka Biotechnologies is a biotechnology company that develops a therapeutic discovery platform using generative AI and high-throughput screening to design and discover antibody therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aureka Biotechnologies Comparables
Compare Aureka Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BigHat Biosciences | 88% | |
| Antiverse | 87% | |
| Infinimmune | 85% |
For institutional investors. Book with your work email.
Aureka Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 10, 2026 | ||||
| Series A Extension | Apr 28, 2026 | ||||
| Series A | Nov 10, 2025 | ||||
| Seed | Mar 1, 2024 | ||||
| Seed | Jun 25, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aureka Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series B |
| BioTrack Capital | Series A Extension |
| Boyuan Capital | Series A Extension |
| Highlight Capital | Series B |
| Granite Asia | Series B |
| 5Y Capital | Series A Extension, Series A |
| NRL Capital | Series A Extension, Series B, Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 119% MoM, reaching 5.9K.
- Aug 10, 2026
$100M round led by Granite Asia.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingAug 11, 2026
Aurekabio received financing of $100M in Series B on Aug 10th '26.
- is_developingAug 10, 2026
Aurekabio is developing a biological world model that simulates biological interactions, allowing researchers to adjust variables and observe reactions without using a pipette, with the potential to shorten drug-development timelines and reduce costs.
For institutional investors. Book with your work email.
Aureka Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aureka Biotechnologies's valuation, stock price, and market status.
Is Aureka Biotechnologies a public or private company?
Aureka Biotechnologies is a private company.
What is the current stock price of Aureka Biotechnologies?
Aureka Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Aureka Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aureka Biotechnologies worth (valuation)?
Valuation information for Aureka Biotechnologies is not publicly available.
Can I buy Aureka Biotechnologies stock?
Aureka Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aureka Biotechnologies's last funding round?
Aureka Biotechnologies's most recent funding round was Series B on August 10, 2026.
Who are the main investors in Aureka Biotechnologies?
Key investors in Aureka Biotechnologies include Granite Asia, 5Y Capital, NRL Capital, 险峰K2VC, Qiming Venture Partners.
Will Aureka Biotechnologies IPO soon?
No public IPO plans have been announced for Aureka Biotechnologies.
How can I track Aureka Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Aureka Biotechnologies's shares on secondary markets.